
Lyndell Lim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8374018/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Time to Uveitis Control with Methotrexate and Mycophenolate Mofetil. Ophthalmology, 2022, 129, 721-723.	2.5	3
2	Genetic Testing of Inherited Retinal Disease in Australian Private Tertiary Ophthalmology Practice. Clinical Ophthalmology, 2022, Volume 16, 1127-1138.	0.9	7
3	Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology, 2021, 128, 899-909.	2.5	25
4	076â $€$ Inflammatory complications of CGRP monoclonal antibodies. , 2021, , .		0
5	Rational laboratory testing in uveitis: A Bayesian analysis. Survey of Ophthalmology, 2021, 66, 802-825.	1.7	8
6	Systemic Associations of Sarcoid Uveitis: Correlation With Uveitis Phenotype and Ethnicity. American Journal of Ophthalmology, 2021, 229, 169-175.	1.7	19
7	The Impact of Adult Uveitis on Quality of Life: An Exploratory Study. Ophthalmic Epidemiology, 2020, 28, 1-9.	0.8	5
8	Diabetic retinopathy progression 6 months postâ€cataract surgery with intravitreous bevacizumab vs triamcinolone: A secondary analysis of the DiMECAT trial. Clinical and Experimental Ophthalmology, 2020, 48, 793-801.	1.3	3
9	Dealing with coâ€existent cataract and diabetic macular oedema: An increasingly common conundrum now solved?. Clinical and Experimental Ophthalmology, 2020, 48, 424-426.	1.3	2
10	Epidemiology of episcleritis and scleritis in urban Australia. Clinical and Experimental Ophthalmology, 2020, 48, 757-766.	1.3	12
11	Clinical Features of Scleritis Across the Asia-Pacific Region. Ocular Immunology and Inflammation, 2019, 27, 920-926.	1.0	22
12	Differences in practice of ophthalmology by gender in Australia. Clinical and Experimental Ophthalmology, 2019, 47, 840-846.	1.3	14
13	Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results. British Journal of Ophthalmology, 2019, 103, bjophthalmol-2018-313437.	2.1	11
14	Epidemiology of uveitis in urban Australia. Clinical and Experimental Ophthalmology, 2019, 47, 733-740.	1.3	26
15	Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen. Ophthalmology, 2019, 126, 723-734.	2.5	222
16	Sarcoidosis-related Uveitis: Clinical Presentation, Disease Course, and Rates of Systemic Disease Progression After Uveitis Diagnosis. American Journal of Ophthalmology, 2019, 198, 30-36.	1.7	45
17	Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Ophthalmology, 2018, 125, 757-773.	2.5	178
18	<i>In Vivo</i> Laser Confocal Microscopy Using the HRT-Rostock Cornea Module: Diversity and Diagnostic Implications in Patients with Uveitis. Ocular Immunology and Inflammation, 2018, 26, 900-909.	1.0	8

Lyndell Lim

#	Article	IF	CITATIONS
19	Risk Factors for Glaucoma in a Cohort of Patients with Fuchs Heterochromic Iridocyclitis. Ocular Immunology and Inflammation, 2017, 25, 753-759.	1.0	10
20	Combined poor diabetes control indicators are associated with higher risks of diabetic retinopathy and macular edema than poor glycemic control alone. PLoS ONE, 2017, 12, e0180252.	1.1	26
21	Long-term Outcomes of Limited Vogt-Koyanagi-Harada Syndrome. American Journal of Ophthalmology, 2016, 167, 52-56.	1.7	6
22	Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. American Journal of Ophthalmology, 2016, 164, 29-36.	1.7	20
23	Association Between Diabetes-Related Eye Complications and Symptoms of Anxiety and Depression. JAMA Ophthalmology, 2016, 134, 1007.	1.4	64
24	Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery – preliminary 6 month results. Clinical and Experimental Ophthalmology, 2016, 44, 233-242.	1.3	30
25	Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2015, 253, 1347-1354.	1.0	14
26	Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. American Journal of Ophthalmology, 2015, 160, 1133-1141.e9.	1.7	35
27	Retrospective analysis of the natural history and management of serpiginous choroiditis in <scp>A</scp> ustralia and <scp>N</scp> ew <scp>Z</scp> ealand. Clinical and Experimental Ophthalmology, 2014, 42, 656-664.	1.3	4
28	Ocular, Aural, and Oral Manifestations. , 2013, , 393-400.		3
29	Patients' Causal Beliefs About Diabetic Retinopathy. Optometry and Vision Science, 2013, 90, 874-882.	0.6	7
30	Proof of Concept, Randomized, Placebo-Controlled Study of the Effect of Simvastatin on the Course of Age-Related Macular Degeneration. PLoS ONE, 2013, 8, e83759.	1.1	67
31	SEROUS RETINAL DETACHMENT AS A COMPLICATION OF ACUTE POSTERIOR MULTIFOCAL PLACOID PIGMENT EPITHELIOPATHY. Retinal Cases and Brief Reports, 2010, 4, 129-131.	0.3	4
32	Intravitreal Methotrexate as Adjunctive, Palliative Therapy in Intraocular T-cell Lymphoma. Ocular Immunology and Inflammation, 2010, 18, 184-186.	1.0	11
33	The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology, 2010, 117, 313-319.e1.	2.5	852
34	Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology, 2010, 117, 1094-1101.e5.	2.5	368
35	Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology, 2010, 117, 1113-1123.e15.	2.5	409
36	Infliximab Therapy for Refractory Uveitis: 2-Year Results of a Prospective Trial. JAMA Ophthalmology, 2009, 127, 819.	2.6	106

Lyndell Lim

#	Article	IF	CITATIONS
37	Cataract surgery in highâ€risk ageâ€related macular degeneration: a randomized controlled trial. Clinical and Experimental Ophthalmology, 2009, 37, 570-576.	1.3	38
38	Non-necrotizing Herpetic Vasculitis. Ophthalmology, 2009, 116, 361-361.e2.	2.5	16
39	Uveitis in Patients with Autoimmune Hepatitis. American Journal of Ophthalmology, 2009, 147, 332-338.e1.	1.7	21
40	Biologic agents in the management of inflammatory eye diseases. Current Allergy and Asthma Reports, 2008, 8, 339-347.	2.4	24
41	Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization. American Journal of Ophthalmology, 2008, 146, 410-416.e1.	1.7	76
42	Prevalence and Risk Factors of Retinal Arteriolar Emboli: The Singapore Malay Eye Study. American Journal of Ophthalmology, 2008, 146, 620-624.	1.7	28
43	Impact of Cataract Surgery on Quality of Life in Patients with Early Age-Related Macular Degeneration. Optometry and Vision Science, 2007, 84, 683-688.	0.6	51
44	Do tumor necrosis factor inhibitors cause uveitis? A registryâ€based study. Arthritis and Rheumatism, 2007, 56, 3248-3252.	6.7	282
45	Non-Invasive Detection of Multinucleated Giant Cells in the Conjunctiva of Patients with Sarcoidosis by In-Vivo Confocal Microscopy. Ocular Immunology and Inflammation, 2006, 14, 203-206.	1.0	7
46	Choroidal Lesions Preceding Symptom Onset in Birdshot Chorioretinopathy. JAMA Ophthalmology, 2006, 124, 1057.	2.6	9
47	Biologic therapies for inflammatory eye disease. Clinical and Experimental Ophthalmology, 2006, 34, 365-374.	1.3	88
48	Primary treatment of choroidal amelanotic melanoma with photodynamic therapy ? response. Clinical and Experimental Ophthalmology, 2006, 34, 721-722.	1.3	1
49	Primary treatment of choroidal amelanotic melanoma with photodynamic therapy. Clinical and Experimental Ophthalmology, 2005, 33, 548-549.	1.3	44
50	HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration?. Survey of Ophthalmology, 2005, 50, 194-206.	1.7	52
51	Test your knowledge. Blunt orbital trauma. Australian Family Physician, 2003, 32, 164-5.	0.5	0